Opinion
Video
A clinical pharmacy specialist examines treatment strategies for EGFR exon 20 insertion mutations, referencing data from the PAPILLON trial, and addresses the challenges associated with managing brain metastases in this patient population.
FDA Approves Osimertinib for Unresectable EGFR-Mutated Lung Cancer